Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 3,416 | 3,883 | 4,287 | 4,889 | 5,241 | 5,849 | 6,717 |
| Operating profit | $m | 829 | 999 | ||||||
| Net profit | $m | - | -154 | -102 | -56 | 254 | 642 | 857 | 1,155 |
| EPS reported | $ | 2.71 | 4.08 | ||||||
| Operating cashflow per share | $ | 5.00 | 6.09 | ||||||
| Capex per share | $ | 0.65 | 0.64 | ||||||
| FCF per share | $ | 4.35 | 5.45 | ||||||
| Free cash flow | $m | 1,031 | 1,034 | ||||||
| Net debt | $m | 1,826 | 1,859 | ||||||
| Book value equity | $m | 8,150 | 8,237 | ||||||
| Book value per share | $ | 34.41 | 43.41 | ||||||
| Number of shares | m | 236.84 | 189.74 | ||||||
| DPS (TTM paid) | $ | 0.45 | 0.45 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 75.45 | - | ||||||
| P/B LTM | x | 5.94 | 5.61 | ||||||
| P/S LTM | x | 9.24 | 7.91 | ||||||
| P/FCF LTM | x | 46.97 | 44.74 | ||||||
| EV/EBITDA LTM | x | 41.19 | 36.29 | ||||||
| EV/Sales LTM | x | 9.62 | 8.23 | ||||||
| Earnings Yield LTM | % | 1.33% | 2.28% | ||||||
| FCF Yield | % | 2.13% | 2.24% | ||||||
| Quality | |||||||||
| ROE | % | 7.88% | 10.46% | ||||||
| ROIC | % | 6.97% | 8.01% | ||||||
| Operating margin | % | 15.82% | 17.08% | ||||||
| Gross margin | % | 68.86% | 66.95% | ||||||
| FCF/Sales | % | 19.67% | 17.67% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +153.27% | +131.82% | ||||||
| Sales Growth YoY | % | +7.20% | +8.98% | ||||||
| Net Income Growth YoY | % | +152.47% | +104.59% | ||||||
| FCF Growth | % | +384.04% | +18.79% | ||||||
| Operating Profit Growth | % | +16.73% | +22.86% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.08% | 0.22% | ||||||
| Dividend Growth | % | +146.33% | +146.33% | ||||||
| Payout Ratio | % | 6.39% | 6.38% | ||||||
| FCF/Debt | x | 0.37 | 0.38 | ||||||
| Net Debt/EBITDA | x | 1.63 | 1.40 | ||||||
| EBIT/Net interest | x | 5.24 | 7.77 | ||||||
| Net debt/market cap | % | 3.77% | 4.02% | ||||||
| Net debt/Equity | x | 0.22 | 0.23 | ||||||
| Gross debt/equity | x | 0.34 | 0.33 | ||||||
ETFs that hold Galderma Group
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| PGIM Jennison International Opportunities ETF | PJIO | 9 | 3.99% |
Funds with Galderma Group among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| PGIM Jennison International Opportunities ETF | PJIO | 9 | 3.99% |
Funds with Galderma Group among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free